[go: up one dir, main page]

SE9802550D0 - Quinoline derivatives - Google Patents

Quinoline derivatives

Info

Publication number
SE9802550D0
SE9802550D0 SE9802550A SE9802550A SE9802550D0 SE 9802550 D0 SE9802550 D0 SE 9802550D0 SE 9802550 A SE9802550 A SE 9802550A SE 9802550 A SE9802550 A SE 9802550A SE 9802550 D0 SE9802550 D0 SE 9802550D0
Authority
SE
Sweden
Prior art keywords
fluoro
hydrogen
iso
formula
prs
Prior art date
Application number
SE9802550A
Other languages
English (en)
Inventor
Anders Bjoerk
Stig Joensson
Tomas Fex
Gunnar Hedlund
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE9802550A priority Critical patent/SE9802550D0/sv
Publication of SE9802550D0 publication Critical patent/SE9802550D0/sv
Priority to ES99935261T priority patent/ES2187176T3/es
Priority to BRPI9912104-2A priority patent/BR9912104B1/pt
Priority to OA1200100012A priority patent/OA11580A/en
Priority to HR20010038A priority patent/HRP20010038A2/hr
Priority to CN99808597A priority patent/CN1114597C/zh
Priority to DK99935261T priority patent/DK1097139T3/da
Priority to UA2000127137A priority patent/UA70944C2/uk
Priority to DE69904333T priority patent/DE69904333T2/de
Priority to NZ508924A priority patent/NZ508924A/xx
Priority to PCT/SE1999/001271 priority patent/WO2000003992A1/en
Priority to JP2000560099A priority patent/JP4082865B2/ja
Priority to HU0103634A priority patent/HUP0103634A3/hu
Priority to APAP/P/2001/002040A priority patent/AP1425A/en
Priority to IDW20010360A priority patent/ID27547A/id
Priority to AT99935261T priority patent/ATE229005T1/de
Priority to TR2001/00086T priority patent/TR200100086T2/xx
Priority to CA002334718A priority patent/CA2334718C/en
Priority to IL14000999A priority patent/IL140009A0/xx
Priority to EEP200100007A priority patent/EE04276B1/xx
Priority to AU50775/99A priority patent/AU745915B2/en
Priority to PT99935261T priority patent/PT1097139E/pt
Priority to KR1020007014281A priority patent/KR100551611B1/ko
Priority to RU2001104344/04A priority patent/RU2213734C2/ru
Priority to HK01104767.2A priority patent/HK1035716B/en
Priority to EP99935261A priority patent/EP1097139B1/en
Priority to YU1401A priority patent/YU1401A/sh
Priority to PL345389A priority patent/PL200147B1/pl
Priority to IS5753A priority patent/IS2187B/is
Priority to ZA200007493A priority patent/ZA200007493B/en
Priority to NO20010210A priority patent/NO317545B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
SE9802550A 1998-07-15 1998-07-15 Quinoline derivatives SE9802550D0 (sv)

Priority Applications (31)

Application Number Priority Date Filing Date Title
SE9802550A SE9802550D0 (sv) 1998-07-15 1998-07-15 Quinoline derivatives
PL345389A PL200147B1 (pl) 1998-07-15 1999-07-14 Związki pochodne chinoliny, zawierające je kompozycje farmaceutyczne, sposób ich wytwarzania i ich zastosowanie
IDW20010360A ID27547A (id) 1998-07-15 1999-07-14 Turunan kuinolin
AT99935261T ATE229005T1 (de) 1998-07-15 1999-07-14 Chinolinderivate
OA1200100012A OA11580A (en) 1998-07-15 1999-07-14 Quinoline derivatives.
HR20010038A HRP20010038A2 (en) 1998-07-15 1999-07-14 Quinoline derivatives
CN99808597A CN1114597C (zh) 1998-07-15 1999-07-14 喹啉衍生物
DK99935261T DK1097139T3 (da) 1998-07-15 1999-07-14 Quinolinderivater
UA2000127137A UA70944C2 (uk) 1998-07-15 1999-07-14 Похідні хіноліну, спосіб їх одержання, фармацевтична композиція та лікарський засіб на їх основі
DE69904333T DE69904333T2 (de) 1998-07-15 1999-07-14 Chinolinderivate
NZ508924A NZ508924A (en) 1998-07-15 1999-07-14 N-phenyl-1,2-dihydro-4-substituted-5-sulfursubstituted-1-alkyl-2-oxo-quinoline-3-carboxamide derivatives, and pharmaceuticals thereof
PCT/SE1999/001271 WO2000003992A1 (en) 1998-07-15 1999-07-14 Quinoline derivatives
JP2000560099A JP4082865B2 (ja) 1998-07-15 1999-07-14 キノリン誘導体
HU0103634A HUP0103634A3 (en) 1998-07-15 1999-07-14 Quinoline derivatives
APAP/P/2001/002040A AP1425A (en) 1998-07-15 1999-07-14 Quinoline derivatives.
ES99935261T ES2187176T3 (es) 1998-07-15 1999-07-14 Derivados de quinolina.
TR2001/00086T TR200100086T2 (tr) 1998-07-15 1999-07-14 Kinolin türevleri.
PT99935261T PT1097139E (pt) 1998-07-15 1999-07-14 Derivados da quinolina
RU2001104344/04A RU2213734C2 (ru) 1998-07-15 1999-07-14 Производные хинолина, способ их получения (варианты), фармацевтическая композиция и способ лечения с их использованием
IL14000999A IL140009A0 (en) 1998-07-15 1999-07-14 Quinoline derivatives
EEP200100007A EE04276B1 (et) 1998-07-15 1999-07-14 Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
AU50775/99A AU745915B2 (en) 1998-07-15 1999-07-14 Quinoline derivatives
BRPI9912104-2A BR9912104B1 (pt) 1998-07-15 1999-07-14 compostos derivados de quinolina, composições farmacêuticas, e, processo para a manufatura de um composto.
KR1020007014281A KR100551611B1 (ko) 1998-07-15 1999-07-14 퀴놀린 유도체
CA002334718A CA2334718C (en) 1998-07-15 1999-07-14 Quinoline derivatives
HK01104767.2A HK1035716B (en) 1998-07-15 1999-07-14 Quinoline derivatives
EP99935261A EP1097139B1 (en) 1998-07-15 1999-07-14 Quinoline derivatives
YU1401A YU1401A (sh) 1998-07-15 1999-07-14 Derivati hinolina
IS5753A IS2187B (is) 1998-07-15 2000-12-05 Quinoline afleiður
ZA200007493A ZA200007493B (en) 1998-07-15 2000-12-14 Quinoline derivatives.
NO20010210A NO317545B1 (no) 1998-07-15 2001-01-12 Kinolinderivater

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802550A SE9802550D0 (sv) 1998-07-15 1998-07-15 Quinoline derivatives

Publications (1)

Publication Number Publication Date
SE9802550D0 true SE9802550D0 (sv) 1998-07-15

Family

ID=20412094

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9802550A SE9802550D0 (sv) 1998-07-15 1998-07-15 Quinoline derivatives

Country Status (30)

Country Link
EP (1) EP1097139B1 (sv)
JP (1) JP4082865B2 (sv)
KR (1) KR100551611B1 (sv)
CN (1) CN1114597C (sv)
AP (1) AP1425A (sv)
AT (1) ATE229005T1 (sv)
AU (1) AU745915B2 (sv)
BR (1) BR9912104B1 (sv)
CA (1) CA2334718C (sv)
DE (1) DE69904333T2 (sv)
DK (1) DK1097139T3 (sv)
EE (1) EE04276B1 (sv)
ES (1) ES2187176T3 (sv)
HR (1) HRP20010038A2 (sv)
HU (1) HUP0103634A3 (sv)
ID (1) ID27547A (sv)
IL (1) IL140009A0 (sv)
IS (1) IS2187B (sv)
NO (1) NO317545B1 (sv)
NZ (1) NZ508924A (sv)
OA (1) OA11580A (sv)
PL (1) PL200147B1 (sv)
PT (1) PT1097139E (sv)
RU (1) RU2213734C2 (sv)
SE (1) SE9802550D0 (sv)
TR (1) TR200100086T2 (sv)
UA (1) UA70944C2 (sv)
WO (1) WO2000003992A1 (sv)
YU (1) YU1401A (sv)
ZA (1) ZA200007493B (sv)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
DE60128936T2 (de) 2000-10-12 2008-04-10 Merck & Co, Inc. Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
NZ525088A (en) 2000-10-12 2004-11-26 Merck & Co Inc Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
AU2003220170B2 (en) 2002-03-15 2008-12-11 Merck Sharp & Dohme Corp. N-(Substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as HIV integrase inhibitors
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
KR101440982B1 (ko) 2005-10-19 2014-09-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 제조방법
US7989473B2 (en) 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US8178127B2 (en) 2007-12-20 2012-05-15 Teva Pharmaceuticals Industries, Ltd. Stable laquinimod preparations
JP2012502038A (ja) 2008-09-03 2012-01-26 テバ ファーマシューティカル インダストリーズ リミティド 免疫機能の２−オキソ−１，２−ジヒドロ−キノリンモジュレーター
MX2012001333A (es) 2009-07-30 2012-06-01 Teva Pharma Tratamiento de la enfermedad de crohn con la laquinimod.
PT2467372T (pt) 2009-08-10 2016-08-23 Teva Pharma Tratamento de distúrbios relacionados com bdnf usando laquinimod
KR20160129093A (ko) 2010-03-03 2016-11-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
SG183513A1 (en) 2010-03-03 2012-09-27 Teva Pharma Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
CN104610144A (zh) 2010-07-09 2015-05-13 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
EP2627638B1 (en) 2010-10-14 2017-07-12 Immunahr AB 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
JP2015505564A (ja) 2012-02-03 2015-02-23 テバ ファーマシューティカル インダストリーズ リミティド 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
US9233927B2 (en) 2013-03-14 2016-01-12 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
WO2021237112A1 (en) * 2020-05-21 2021-11-25 Stemsynergy Therapeutics, Inc. Notch inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
DE4120646A1 (de) * 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
SE469368B (sv) * 1991-10-09 1993-06-28 Kabi Pharmacia Ab Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms)
CN1063686A (zh) * 1992-03-12 1992-08-19 华西医科大学药物研究所 用活性酯法合成维司力农
SE9201076L (sv) * 1992-04-06 1993-10-07 Shimon Slavin Användningen av gamla läkemedel för behandling av diabetes
JPH07224040A (ja) * 1994-02-07 1995-08-22 Fujisawa Pharmaceut Co Ltd キノリン誘導体
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives

Also Published As

Publication number Publication date
WO2000003992A1 (en) 2000-01-27
IS5753A (is) 2000-12-05
CN1309640A (zh) 2001-08-22
IS2187B (is) 2006-12-15
DE69904333D1 (de) 2003-01-16
DK1097139T3 (da) 2002-12-30
PL345389A1 (en) 2001-12-17
IL140009A0 (en) 2002-02-10
YU1401A (sh) 2003-10-31
ES2187176T3 (es) 2003-05-16
HK1035716A1 (en) 2001-12-07
BR9912104B1 (pt) 2010-07-13
ZA200007493B (en) 2001-06-19
HUP0103634A3 (en) 2002-03-28
EP1097139B1 (en) 2002-12-04
AU5077599A (en) 2000-02-07
TR200100086T2 (tr) 2001-05-21
JP2002520396A (ja) 2002-07-09
AP2001002040A0 (en) 2001-03-31
KR100551611B1 (ko) 2006-02-13
EE200100007A (et) 2002-06-17
CA2334718C (en) 2006-11-21
HRP20010038A2 (en) 2001-12-31
NO20010210D0 (no) 2001-01-12
NZ508924A (en) 2002-09-27
JP4082865B2 (ja) 2008-04-30
OA11580A (en) 2004-07-01
UA70944C2 (uk) 2004-11-15
EP1097139A1 (en) 2001-05-09
NO20010210L (no) 2001-03-15
PL200147B1 (pl) 2008-12-31
PT1097139E (pt) 2003-04-30
BR9912104A (pt) 2001-05-02
HUP0103634A2 (hu) 2002-02-28
CA2334718A1 (en) 2000-01-27
CN1114597C (zh) 2003-07-16
EE04276B1 (et) 2004-04-15
AP1425A (en) 2005-06-06
RU2213734C2 (ru) 2003-10-10
AU745915B2 (en) 2002-04-11
ID27547A (id) 2001-04-12
DE69904333T2 (de) 2003-10-16
ATE229005T1 (de) 2002-12-15
NO317545B1 (no) 2004-11-15
KR20010071491A (ko) 2001-07-28

Similar Documents

Publication Publication Date Title
SE9802550D0 (sv) Quinoline derivatives
SE9802549D0 (sv) Quinoline derivatives
SE9801474D0 (sv) Quinoline Derivatives
ATE209186T1 (de) Überbrückte azabicyclische derivate als substanz p antagonisten
IS2750B (is) Leiðarafesting
DE69410092D1 (en) Phenyl heterocyclen als cyclooxygenase-2 inhibitoren
KR930016421A (ko) 퀴놀론- 및 나프티리돈-카르복실산 유도체
ATE28872T1 (de) Neue imidazol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
ATE109466T1 (de) Neue derivate des aminopiperidins, aminopyrrolidins und des aminoperhydroazepins, verfahren zur herstellung und diese enthaltende arzneimittel.
DE69732571D1 (de) Beta-sulfonyl-hydroxamsäuren als matrix-metalloproteinaseinhibitoren
GR1001619B (el) Παράγωγα ινδόλης.
ID21775A (id) Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
CA2221114A1 (en) Atherosclerosis treatment
IS2125B (is) Frumuviðloðunar-bælandi bólgu-eyðandi og ónæmisbælandi efnasambönd
AU6427800A (en) Fungicidal combinations
DK0556813T3 (da) Amfotere tricykliske forbindelser som antihistaminske og antiallergiske midler
CA2366829A1 (fr) Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant
DE3887102D1 (de) Substituierte Derivate von 20,21-Dinoreburnamenin, Verfahren zur Herstellung und so hergestellte Zwischenprodukte, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammenstellungen.
DE69110219D1 (de) 3-(1H-Indazol-3-yl)-4-pyridiname, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
EP1632228A4 (en) MEDICINAL COMPOSITION CONTAINING TRIAZOLE COMPOUND
DE69706441D1 (de) Tetracyclische aromatische retinoide verbindungen, ihre herstellung und verwendung
TNSN08233A1 (en) Bicyclic cinnamide compound
FI931938A0 (fi) Mellanprodukter vid framstaellning av 4,5-difluorantranilinsyra
ATE30675T1 (de) Benzobicyclononanamin-derivate mit antikonvulsiven eigenschaften.
KR970001360A (ko) 피리딘을 함유한 티에노피리미돈 유도체